Developer docs
API playgroundTry for free, no card

Search company profiles

Positrigo

Full company profile

uuid0000bi2

Namestring
Positrigo
Legal namestring
Positrigo AG
Websiteurl
positrigo.com
Company typeenum
Private
Founded yearint
2018
Descriptiontext

Positrigo AG is a Swiss medical device company founded in 2018 as a spin-off of ETH Zurich, headquartered at Technopark Zurich with a US subsidiary opened in October 2023. The company designs, manufactures, and sells the NeuroLF, an ultra-compact dedicated brain Positron Emission Tomography (PET) scanner that uses silicon photomultiplier (SiPM) detectors and proprietary reconstruction algorithms to enable functional brain imaging at a fraction of the cost, size, and infrastructure requirements of conventional whole-body PET systems. The NeuroLF received FDA 510(k) clearance in July 2024 and CE Mark in October 2024, and is sold primarily to neurology practices, memory and dementia centers, outpatient imaging clinics, and academic medical centers for applications including Alzheimer's disease and other dementias, neuro-oncology, epilepsy, and movement disorders.

Positrigo's revenue model combines capital equipment sales of the NeuroLF system with recurring revenue from service and maintenance contracts (Complete and Preventive Service Programs) and clinical training and application support services. Go-to-market is executed through direct enterprise field sales in the US and key European markets (including a US subsidiary and named reference accounts such as The Neuron Clinic, Beverly Hills Medical Imaging, LMU Hospital Munich, and University Hospital of Genoa), complemented by regional distribution partners APR Salud in Spain and Qualimedis in France. The company invests in clinical education via the Brain PET Talks webinar series, presence at major medical conferences (SNMMI, AAIC, EANM, CTAD, RSNA), whitepapers, and KOL engagement.

The company is venture-backed with approximately CHF 14M+ in disclosed equity and grant funding across rounds led by 4FO Venture Partners, 4FOX Ventures, Zurcher Kantonalbank, ETH Zurich Foundation, HealthCap, and Navivo Capital, supplemented by European Innovation Council and Innosuisse non-dilutive funding. The board includes former Siemens Healthcare CEO Urs Suter as Chairman and senior healthcare operators from GE Healthcare, Siemens, and Roche-affiliated entities, reflecting a deliberate build toward scaled commercialization rather than a research-stage posture.

Short descriptiontext

Positrigo AG develops and sells the NeuroLF, an FDA-cleared and CE-marked ultra-compact dedicated brain PET scanner for neurology practices, imaging centers, and hospitals diagnosing Alzheimer's and other brain disorders.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersZürich, Switzerland
HQ citystring
Zürich
HQ countrystring
Switzerland
HQ regionstring
Europe
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
dedicated brain PET, medical imaging devices, functional brain imaging, PET scanners, dementia diagnostic imaging
Industry3 codes
1Point-of-Care (POC) & Rapid Diagnostics (near-patient, lateral flow)
CodeHLAAALAGPrimaryYes
2Point-of-Care Testing (POCT) & Near-Patient Labs
CodeHLAFAMAIPrimaryNo
3Remote Diagnostics & Point-of-Care (Connected Testing, Home Lab Devices)
CodeHLACAPAKPrimaryNo
NAICS code1 code
  • Medical and Diagnostic Laboratories62151
SIC code1 code
  • Surgical & Medical Instruments & Apparatus3841
Product category
Nuclear Medicine Imaging Equipment
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model3 records
1NeuroLF System Hardware Sales
TypeHardware Sales
Description

Sale of the NeuroLF dedicated brain PET scanner to healthcare providers including neurology practices, imaging centers, and hospitals. The system is sold as a capital equipment purchase with one-time revenue per unit sold.

positrigo.com
2Service and Maintenance Contracts
TypeSubscription Recurring
Description

Annual service programs including preventive maintenance and technical support. Two service tiers offered: Complete Service Program (covers all technical service costs including annual maintenance inspection) and Preventive Service Program. First year includes factory warranty and free preventive maintenance visit.

positrigo.com
3Clinical Training and Support Services
TypeProfessional Services
Description

On-demand clinical training for new staff, continuing education opportunities for trained clinicians, and ongoing clinical application support to ensure efficient system utilization from day one.

positrigo.com
Marketing channels7 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels4 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain, Infrastructure
Pricing details1 tier
1NeuroLF System - Capital Equipment
ModelOne time/ perpetual licenseBilling cadenceMulti-year contract
Notes

No public pricing available. Sales through direct enterprise sales with custom quotes. Target buyers include neurology practices, imaging centers, and hospitals.

positrigo.com
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 record
1NeuroLF
Description

Ultra-compact dedicated brain Positron Emission Tomography (PET) system designed for functional brain imaging, applicable in dementia diagnosis (including Alzheimer's), neuro-oncology, epilepsy, movement disorders, and research.

positrigo.com
Core offering1 text field

Positrigo develops, manufactures, and sells the NeuroLF, an ultra-compact dedicated brain Positron Emission Tomography (PET) scanner designed for functional brain imaging at the point of care. The system is FDA cleared and CE marked for clinical brain imaging, particularly dementia diagnosis including Alzheimer's disease, with applications in neuro-oncology, epilepsy, movement disorders, and research. Positrigo also provides clinical training/education services and recurring technical maintenance programs as supporting offerings.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • 9 out of 10 patients prefer sitting position during scanning vs lying down required by conventional PET systems
+3 more records
Product overview1 text field

Positrigo offers a focused portfolio centered on the NeuroLF system, an ultra-compact dedicated brain PET scanner that enables functional brain imaging at a fraction of the cost and space requirements of whole-body PET systems. The product suite includes the NeuroLF hardware system as the core offering, supported by clinical services (training, education, and ongoing support) and technical maintenance services. The NeuroLF system is FDA-cleared and CE-marked, targeting markets in the US and Europe for applications including dementia diagnosis (Alzheimer's disease), neuro-oncology, epilepsy, movement disorders, and clinical research.

Product and service3 records
1NeuroLF Brain PET System
CategoryMedical Imaging Hardware / Capital Equipment
Description

Ultra-compact dedicated brain Positron Emission Tomography (PET) scanner for point-of-care functional brain imaging. FDA cleared and CE marked. Indicated for clinical brain imaging including dementia diagnosis (Alzheimer's disease, Lewy body, vascular, frontotemporal dementias), neuro-oncology, epilepsy, movement disorders, and research applications. Designed for installation in neurology practices and outpatient imaging centers with limited space requirements, intuitive usability, and a seated patient position.

2Clinical Services
CategoryProfessional Services / Clinical Training
Description

Clinical training and ongoing application support for NeuroLF customers, including initial product training, on-demand training for new staff, continuing education opportunities for trained clinicians, webinars (Brain PET Talks), case studies, and clinical whitepapers to ensure efficient system utilization from day one. Targeted at clinical users and nuclear medicine teams at NeuroLF customer sites.

3Technical Maintenance Services
CategoryTechnical Service / Maintenance Contracts
Description

Annual technical service programs for installed NeuroLF systems. Includes a Complete Service Program (covers all technical service costs including annual maintenance inspection) and a Preventive Service Program. First year of ownership includes a factory warranty and a free preventive maintenance visit. Provided to NeuroLF customer sites to maintain uptime and performance.

Scale indicator8 records

Each record includes

Type, Value, Description, Source

Recent move8 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight7 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Global leader in medical imaging including whole-body PET/CT and PET/MR. Sells the broadest installed base of clinical PET scanners worldwide and previously developed the ECAT HRRT dedicated brain PET. Competes with Positrigo for brain imaging volume, but lacks Positrigo's point-of-care compact form factor and outpatient workflow fit. Positrigo's chairman Urs Suter is a former Siemens Healthcare CEO.

TypeBroad incumbent
Description

Major PET/CT and PET/MR manufacturer with broad hospital and imaging-center footprint. Two of Positrigo's commercial leaders (Global CCO Jerome Descheirder and VP US Sales Brian Oswald) previously held senior roles at GE HealthCare, indicating the talent and customer relationships overlap. Competes with Positrigo on oncology-dominated whole-body PET scanners that also serve brain imaging.

TypeBroad incumbent
Description

Global medical imaging incumbent selling PET/CT and PET/MR systems alongside a broad diagnostic imaging portfolio. Competes for hospital and imaging center capital equipment budgets that could otherwise be deployed for Positrigo's NeuroLF, though Philips does not offer a dedicated brain-only PET system.

TypeDirect peer
Description

Chinese-headquartered medical imaging company rapidly expanding in PET/CT and PET/MR, including dedicated head/neuro PET configurations (e.g., uMI-Panvivo and brain-focused systems). Most direct head-to-head competitor in dedicated brain PET positioning globally, with broader product portfolio and aggressive pricing.

TypeBroad incumbent
Description

Sells PET/CT systems as part of a broad diagnostic imaging portfolio (formerly Toshiba Medical). Competes with Positrigo for clinical brain imaging referrals through hospital-based whole-body PET installations, though Canon does not currently offer a dedicated point-of-care brain PET.

TypeEmerging player
Description

Canadian-based developer of compact preclinical PET scanners for research and translational imaging. Comparable to Positrigo in miniaturization and SiPM detector focus, though Cubresa targets research institutions and preclinical applications rather than clinical brain imaging. Represents a relevant technical peer in compact PET engineering.

TypeOthers
Description

Major scientific instruments company with a significant preclinical PET and PET/MR business (legacy Bruker Biospin / PET technology). Sells compact PET systems primarily to research institutions and pharmaceutical R&D, overlapping with Positrigo's research customer segment but not directly competing in clinical brain imaging.

TypeOthers
Description

Hungarian medical imaging company selling preclinical and clinical PET, SPECT, and hybrid systems. Offers compact and dedicated organ-focused imaging systems that share Positrigo's philosophy of purpose-built imaging. Primarily preclinical/clinical research focus, with some specialty clinical applications overlapping with NeuroLF's research use cases.

TypeOthers
Description

Leading vendor of PET and SPECT image processing, quantification, and visualization software widely used in nuclear medicine and neurology. Complementary rather than competitive with Positrigo, as Hermes software is often deployed alongside PET scanners including NeuroLF for clinical interpretation and quantification (Centiloid scaling, amyloid/tau analysis).

TypeEmerging player
Description

US-based company developing PET-guided radiation therapy systems for oncology. Shares the PET imaging engineering heritage and ETH Zurich spin-off DNA with Positrigo, though its application (radiotherapy guidance) is materially different. Reflects the broader innovation wave in dedicated and PET-integrated medical imaging devices.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers5 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment6 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles9 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries1 record

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance1 record

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds10 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors12 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Positrigo

Nuclear Medicine Imaging Equipmentpositrigo.com

Positrigo AG develops and sells the NeuroLF, an FDA-cleared and CE-marked ultra-compact dedicated brain PET scanner for neurology practices, imaging centers, and hospitals diagnosing Alzheimer's and other brain disorders.

What Positrigo does

Positrigo AG is a Swiss medical device company founded in 2018 as a spin-off of ETH Zurich, headquartered at Technopark Zurich with a US subsidiary opened in October 2023. The company designs, manufactures, and sells the NeuroLF, an ultra-compact dedicated brain Positron Emission Tomography (PET) scanner that uses silicon photomultiplier (SiPM) detectors and proprietary reconstruction algorithms to enable functional brain imaging at a fraction of the cost, size, and infrastructure requirements of conventional whole-body PET systems. The NeuroLF received FDA 510(k) clearance in July 2024 and CE Mark in October 2024, and is sold primarily to neurology practices, memory and dementia centers, outpatient imaging clinics, and academic medical centers for applications including Alzheimer's disease and other dementias, neuro-oncology, epilepsy, and movement disorders.

Positrigo's revenue model combines capital equipment sales of the NeuroLF system with recurring revenue from service and maintenance contracts (Complete and Preventive Service Programs) and clinical training and application support services. Go-to-market is executed through direct enterprise field sales in the US and key European markets (including a US subsidiary and named reference accounts such as The Neuron Clinic, Beverly Hills Medical Imaging, LMU Hospital Munich, and University Hospital of Genoa), complemented by regional distribution partners APR Salud in Spain and Qualimedis in France. The company invests in clinical education via the Brain PET Talks webinar series, presence at major medical conferences (SNMMI, AAIC, EANM, CTAD, RSNA), whitepapers, and KOL engagement.

The company is venture-backed with approximately CHF 14M+ in disclosed equity and grant funding across rounds led by 4FO Venture Partners, 4FOX Ventures, Zurcher Kantonalbank, ETH Zurich Foundation, HealthCap, and Navivo Capital, supplemented by European Innovation Council and Innosuisse non-dilutive funding. The board includes former Siemens Healthcare CEO Urs Suter as Chairman and senior healthcare operators from GE Healthcare, Siemens, and Roche-affiliated entities, reflecting a deliberate build toward scaled commercialization rather than a research-stage posture.

Positrigo firmographics

Firmographics
Name
Positrigo
Legal name
Positrigo AG
Website
https://positrigo.com
Company type
Private
Founded year
2018
Operating status
Operating
Headcount range
11–50 employees
Short description
Positrigo AG develops and sells the NeuroLF, an FDA-cleared and CE-marked ultra-compact dedicated brain PET scanner for neurology practices, imaging centers, and hospitals diagnosing Alzheimer's and other brain disorders.
Ownership category
akta.pro rank

Positrigo industry classification

Industry
Product category
Nuclear Medicine Imaging Equipment
NAICS
Medical and Diagnostic Laboratories (62151)
SIC
Surgical & Medical Instruments & Apparatus (3841)
akta.pro primary industry
Point-of-Care (POC) & Rapid Diagnostics (near-patient, lateral flow) (HLAAALAG)
akta.pro secondary industries
Point-of-Care Testing (POCT) & Near-Patient Labs (HLAFAMAI), Remote Diagnostics & Point-of-Care (Connected Testing, Home Lab Devices) (HLACAPAK)

Keywords

  • Dedicated brain PET
  • Medical imaging devices
  • Functional brain imaging
  • PET scanners
  • Dementia diagnostic imaging

Where Positrigo is headquartered

Location

Headquarters

HQ city
Zürich
HQ country
Switzerland
HQ region
Europe

Offices2 records

Markets served

Positrigo business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain, Infrastructure

Revenue model

  1. NeuroLF System Hardware Sales: Sale of the NeuroLF dedicated brain PET scanner to healthcare providers including neurology practices, imaging centers, and hospitals. The system is sold as a capital equipment purchase with one-time revenue per unit sold.
  2. Service and Maintenance Contracts: Annual service programs including preventive maintenance and technical support. Two service tiers offered: Complete Service Program (covers all technical service costs including annual maintenance inspection) and Preventive Service Program. First year includes factory warranty and free preventive maintenance visit.
  3. Clinical Training and Support Services: On-demand clinical training for new staff, continuing education opportunities for trained clinicians, and ongoing clinical application support to ensure efficient system utilization from day one.

Pricing tiers

ModelBillingPrice
One time/ perpetual licenseMulti-year contractNeuroLF System - Capital Equipment

Go-to-market motion2 records

Distribution channels4 records

Marketing channels7 records

Positrigo product offering

Product offering

Core offering

Positrigo develops, manufactures, and sells the NeuroLF, an ultra-compact dedicated brain Positron Emission Tomography (PET) scanner designed for functional brain imaging at the point of care. The system is FDA cleared and CE marked for clinical brain imaging, particularly dementia diagnosis including Alzheimer's disease, with applications in neuro-oncology, epilepsy, movement disorders, and research. Positrigo also provides clinical training/education services and recurring technical maintenance programs as supporting offerings.

Product overview

Positrigo offers a focused portfolio centered on the NeuroLF system, an ultra-compact dedicated brain PET scanner that enables functional brain imaging at a fraction of the cost and space requirements of whole-body PET systems. The product suite includes the NeuroLF hardware system as the core offering, supported by clinical services (training, education, and ongoing support) and technical maintenance services. The NeuroLF system is FDA-cleared and CE-marked, targeting markets in the US and Europe for applications including dementia diagnosis (Alzheimer's disease), neuro-oncology, epilepsy, movement disorders, and clinical research.

Differentiator

Problem solved

Functional benefit

Brands

  • NeuroLF: Ultra-compact dedicated brain Positron Emission Tomography (PET) system designed for functional brain imaging, applicable in dementia diagnosis (including Alzheimer's), neuro-oncology, epilepsy, movement disorders, and research.

Products and services

  • NeuroLF Brain PET System Ultra-compact dedicated brain Positron Emission Tomography (PET) scanner for point-of-care functional brain imaging. FDA cleared and CE marked. Indicated for clinical brain imaging including dementia diagnosis (Alzheimer's disease, Lewy body, vascular, frontotemporal dementias), neuro-oncology, epilepsy, movement disorders, and research applications. Designed for installation in neurology practices and outpatient imaging centers with limited space requirements, intuitive usability, and a seated patient position.
  • Clinical Services Clinical training and ongoing application support for NeuroLF customers, including initial product training, on-demand training for new staff, continuing education opportunities for trained clinicians, webinars (Brain PET Talks), case studies, and clinical whitepapers to ensure efficient system utilization from day one. Targeted at clinical users and nuclear medicine teams at NeuroLF customer sites.
  • Technical Maintenance Services Annual technical service programs for installed NeuroLF systems. Includes a Complete Service Program (covers all technical service costs including annual maintenance inspection) and a Preventive Service Program. First year of ownership includes a factory warranty and a free preventive maintenance visit. Provided to NeuroLF customer sites to maintain uptime and performance.

Quantifiable outcome

  • 9 out of 10 patients prefer sitting position during scanning vs lying down required by conventional PET systems
  • +3 more outcomes

Companies that use Positrigo

Customer profile

Named customers5 records

Segments6 records

Ideal customer profiles3 records

Positrigo technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

Positrigo partnerships and signals

Strategic signal

Scale indicators8 records

Recent moves8 records

Expansion highlights7 records

Positrigo competitors and assessment

Company assessment

Broad incumbents

  • Siemens Healthineers: Global leader in medical imaging including whole-body PET/CT and PET/MR. Sells the broadest installed base of clinical PET scanners worldwide and previously developed the ECAT HRRT dedicated brain PET. Competes with Positrigo for brain imaging volume, but lacks Positrigo's point-of-care compact form factor and outpatient workflow fit. Positrigo's chairman Urs Suter is a former Siemens Healthcare CEO.
  • GE HealthCare: Major PET/CT and PET/MR manufacturer with broad hospital and imaging-center footprint. Two of Positrigo's commercial leaders (Global CCO Jerome Descheirder and VP US Sales Brian Oswald) previously held senior roles at GE HealthCare, indicating the talent and customer relationships overlap. Competes with Positrigo on oncology-dominated whole-body PET scanners that also serve brain imaging.
  • Philips: Global medical imaging incumbent selling PET/CT and PET/MR systems alongside a broad diagnostic imaging portfolio. Competes for hospital and imaging center capital equipment budgets that could otherwise be deployed for Positrigo's NeuroLF, though Philips does not offer a dedicated brain-only PET system.
  • Canon Medical Systems: Sells PET/CT systems as part of a broad diagnostic imaging portfolio (formerly Toshiba Medical). Competes with Positrigo for clinical brain imaging referrals through hospital-based whole-body PET installations, though Canon does not currently offer a dedicated point-of-care brain PET.

Direct peers

  • United Imaging Healthcare: Chinese-headquartered medical imaging company rapidly expanding in PET/CT and PET/MR, including dedicated head/neuro PET configurations (e.g., uMI-Panvivo and brain-focused systems). Most direct head-to-head competitor in dedicated brain PET positioning globally, with broader product portfolio and aggressive pricing.

Emerging players

  • Cubresa: Canadian-based developer of compact preclinical PET scanners for research and translational imaging. Comparable to Positrigo in miniaturization and SiPM detector focus, though Cubresa targets research institutions and preclinical applications rather than clinical brain imaging. Represents a relevant technical peer in compact PET engineering.
  • RefleXion Medical: US-based company developing PET-guided radiation therapy systems for oncology. Shares the PET imaging engineering heritage and ETH Zurich spin-off DNA with Positrigo, though its application (radiotherapy guidance) is materially different. Reflects the broader innovation wave in dedicated and PET-integrated medical imaging devices.

Others

  • Bruker: Major scientific instruments company with a significant preclinical PET and PET/MR business (legacy Bruker Biospin / PET technology). Sells compact PET systems primarily to research institutions and pharmaceutical R&D, overlapping with Positrigo's research customer segment but not directly competing in clinical brain imaging.
  • Mediso Medical Imaging Systems: Hungarian medical imaging company selling preclinical and clinical PET, SPECT, and hybrid systems. Offers compact and dedicated organ-focused imaging systems that share Positrigo's philosophy of purpose-built imaging. Primarily preclinical/clinical research focus, with some specialty clinical applications overlapping with NeuroLF's research use cases.
  • Hermes Medical Solutions: Leading vendor of PET and SPECT image processing, quantification, and visualization software widely used in nuclear medicine and neurology. Complementary rather than competitive with Positrigo, as Hermes software is often deployed alongside PET scanners including NeuroLF for clinical interpretation and quantification (Centiloid scaling, amyloid/tau analysis).

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Positrigo social profiles

Digital presence

Positrigo compliance and trust

Trust signal

Compliance1 record

Positrigo financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Positrigo leadership team

Management profile

Number of profiles

Profiles9 records

Positrigo subsidiaries and ownership

Company hierarchy

Subsidiaries1 record

Positrigo funding detail

Funding detail

Funding overview

Funding rounds10 records

Investors12 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Positrigo M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Positrigo

What does Positrigo do?

Positrigo develops, manufactures, and sells the NeuroLF, an ultra-compact dedicated brain Positron Emission Tomography (PET) scanner designed for functional brain imaging at the point of care. The system is FDA cleared and CE marked for clinical brain imaging, particularly dementia diagnosis including Alzheimer's disease, with applications in neuro-oncology, epilepsy, movement disorders, and research. Positrigo also provides clinical training/education services and recurring technical maintenance programs as supporting offerings.

Is Positrigo a public or private company?

Positrigo is a private company. It is classified as venture growth investor backed and is currently operating.

When was Positrigo founded?

Positrigo was founded in 2018. It employs 11 to 50 people.

Where is Positrigo based?

Positrigo is headquartered in Zürich, Switzerland, in the Europe region.

How does Positrigo make money?

Three revenue lines are on record. NeuroLF System Hardware Sales are the primary driver. The others are service and Maintenance Contracts and clinical Training and Support Services.

Who are Positrigo's main competitors?

Broad incumbents on record are Siemens Healthineers, GE HealthCare, Philips and Canon Medical Systems. United Imaging Healthcare is listed as a direct peer. Emerging players are Cubresa and RefleXion Medical. Others are Bruker, Mediso Medical Imaging Systems and Hermes Medical Solutions.

Does Positrigo have an API?

No public API is recorded for Positrigo.

What industry is Positrigo in?

Positrigo's product category is Nuclear Medicine Imaging Equipment. Its primary akta.pro industry code is HLAAALAG, Point-of-Care (POC) & Rapid Diagnostics (near-patient, lateral flow), with a secondary code of HLAFAMAI, Point-of-Care Testing (POCT) & Near-Patient Labs. Its NAICS code is 62151 and its SIC code is 3841.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
startupticker.chMajor developments for three Swiss Medtech startupsOxyPrem's NOAH tissue oximeter received CE marking and is commercially available in Europe. Positrigo's NeuroLF brain PET system achieved EARL accreditation, becoming the first dedicated brain PET system to do so. MindMaze reported positive results from a Vibra Healthcare study, supporting its upcoming MindMotion Lite launch.startupticker.chTwo startups make progress in clinical researchPeriVision and Positrigo are advancing their clinical technologies, with PeriVision reporting that its VR-based VisionOne platform matches the gold standard in glaucoma testing and Positrigo securing approval for its NeuroLF brain PET scanner in an Alzheimer's trial. These developments highlight significant progress for both companies as they expand commercial traction and clinical research applications across Europe and beyond.startupticker.chPositrigo on a growth momentum in the USOne year after acquiring its first US customer, Positrigo has installed multiple NeuroLF brain PET scanner systems at client facilities, with Beverly Hills Medical Imaging and The Neuron Clinic in California being recent adopters of the technology. The company has also expanded into Europe with sales in Germany and Italy and appointed new distributors in Spain and France, while strengthening its leadership team with three new executives. Positrigo is currently fundraising through an equity investment round with participation from venture capital firm Kineo Finance.PositrigoPositrigo closes Financing Round and appoints new Board MembersPositrigo, a Swiss medical device company developing nuclear brain imaging technology, closed an oversubscribed financing round of 7 million CHF and appointed three new board members. The funding, led by venture capital firms HealthCap and Navivo, will accelerate production and commercialization of the NeuroLF brain PET system in the US and EU markets. The company's NeuroLF device is the first dedicated brain PET scanner to receive market clearance in both the US and EU, targeting the growing Alzheimer's disease diagnostic market projected to affect 150 million people by 2050.startupticker.chPositrigo ready for the commercialisation phase after raising CHF 5.5 millionPositrigo has secured CHF 5.5 million in Series B financing led by Fairway Asset Management to finalize market approvals for its NeuroLF brain PET system in Europe and the US. The capital will enable the Zurich-based startup to establish commercialization structures and prepare for the product launch of its ultra-compact imaging device.PositrigoPositrigo closes successfully Series B Funding Round.Positrigo, a Zurich-based nuclear medical imaging company, announced on October 24, 2022 that it raised CHF 5.5 million in a first closing of its Series B round, led by Fairway Asset Management and supported by 4FO Venture Partners, the EIC Fund, Zürcher Kantonalbank and the ETH Foundation. The funding brings total raised to over CHF 13 million and will fund CE-mark approval in Europe and FDA clearance in the US for its NeuroLF brain PET scanner.startupticker.chAdditional funds for PositrigoPositrigo, an ETH Zurich spinoff, has secured an additional EUR 1.5 million in equity funding from the European Innovation Council (EIC) Fund to support its Series A financing and commercialize its ultra-compact brain PET scanner technology. This investment follows a previous grant and aims to accelerate the market entry of the NeuroLF device for early detection of Alzheimer's disease. The company successfully completed its first in-vivo clinical trials with partners at University Hospital Zurich and ETH Zurich.